fingolimod (Gilenya) vs Ponesimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline

fingolimod (Gilenya)

Marketed by Novartis and partners

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT00289978 · Phase 3 · completed

This was a large randomized, triple-blind, placebo-controlled Phase 3 trial in 1,272 people with multiple sclerosis, using the annualized relapse rate as its primary measure. Both fingolimod doses roughly halved that rate against placebo: 0.16 relapses per year (95% CI 0.13 to 0.19) on 1.25 mg and 0.18 (95% CI 0.15 to 0.22) on 0.5 mg, against 0.40 (95% CI 0.34 to 0.47) on placebo. The registry posts these rates without a statistical test, but the intervals do not overlap, so the direction of the effect is not in doubt.

Next expected readout: January 2030 · NCT07220252 (registry estimate)

Reported efficacy

Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47) (met)

Result source: NCT00289978

Ponesimod

Marketed by Vanda Pharmaceuticals and partners

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT02425644 · Phase 3 · completed

This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.

Reported efficacy

Annualized Confirmed Relapse Rate (From randomization to end of study (Week 108)): Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001. (met)

Result source: NCT02425644

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfingolimod (Gilenya)Ponesimod
Annualised relapse rate0.2 vs 0.4−0.2 vs placebo0.5 mg · wk 104 · n 425NCT00289978
5 other results
  • 0.2 vs 0.4 0.5 mg · wk 104 · n 358 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 429 · Phase 3 · primary NCT00289978
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 370 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 0.5 mg · wk 234 · n 358 · Phase 3 · secondary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 234 · n 370 · Phase 3 · secondary NCT00355134
0.2 vs 0.3vs Teriflunomide20 mg · wk 108 · n 567NCT02425644
Free of 3-month confirmed disability progression (%)82.3% vs 75.9%+6.4 vs placebo0.5 mg · wk 104 · n 425NCT00289978
3 other results
  • 74.7% vs 71% 0.5 mg · wk 104 · n 358 · Phase 3 · secondary NCT00355134
  • 83.4% vs 75.9% 1.25 mg · wk 104 · n 429 · Phase 3 · secondary NCT00289978
  • 78.3% vs 71% 1.25 mg · wk 104 · n 370 · Phase 3 · secondary NCT00355134
—Not reported
New or enlarging T2 lesions2.5 vs 9.8−7.3 vs placebo0.5 mg · wk 104 · n 370NCT00289978
1 other result
  • 2.5 vs 9.8 1.25 mg · wk 104 · n 337 · Phase 3 · secondary NCT00289978
—Not reported

Annualised relapse rate

fingolimod (Gilenya)
0.2 vs 0.4−0.2 vs placebo0.5 mg · wk 104 · n 425NCT00289978
5 other results
  • 0.2 vs 0.4 0.5 mg · wk 104 · n 358 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 429 · Phase 3 · primary NCT00289978
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 370 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 0.5 mg · wk 234 · n 358 · Phase 3 · secondary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 234 · n 370 · Phase 3 · secondary NCT00355134
Ponesimod
0.2 vs 0.3vs Teriflunomide20 mg · wk 108 · n 567NCT02425644

Free of 3-month confirmed disability progression (%)

fingolimod (Gilenya)
82.3% vs 75.9%+6.4 vs placebo0.5 mg · wk 104 · n 425NCT00289978
3 other results
  • 74.7% vs 71% 0.5 mg · wk 104 · n 358 · Phase 3 · secondary NCT00355134
  • 83.4% vs 75.9% 1.25 mg · wk 104 · n 429 · Phase 3 · secondary NCT00289978
  • 78.3% vs 71% 1.25 mg · wk 104 · n 370 · Phase 3 · secondary NCT00355134
Ponesimod
—Not reported

New or enlarging T2 lesions

fingolimod (Gilenya)
2.5 vs 9.8−7.3 vs placebo0.5 mg · wk 104 · n 370NCT00289978
1 other result
  • 2.5 vs 9.8 1.25 mg · wk 104 · n 337 · Phase 3 · secondary NCT00289978
Ponesimod
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. fingolimod (Gilenya): 6 of 6 rows · Ponesimod: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfingolimod (Gilenya)
Rows use multiple source trials
Ponesimod
Rows use multiple source trials
Annualized Relapse
event rate · per year
No placebo or comparator arm
0.169 per year @ 676wk0.5 mg/Daya,b,c,d
NCT01201356 · Phase 3 · registry result, not featured evidence
0.142 per year20 mge,a,b,c,d
NCT01093326 · Phase 2 · registry result, not featured evidence
show 2 more doses
0.15 per year40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
0.205 per year10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Time to First Relapse
time to event · months
No placebo or comparator arm
NA monthse,f,b,c,d
NCT01498887 · Phase 4 · registry result, not featured evidence
show 1 more dose
NA months
NCT01498887 · Phase 4 · registry result, not featured evidence
151.55 months*20 mge,f,b,c,d
NCT01093326 · Phase 2 · registry result, not featured evidence · converted to months from 656.7 weeks as posted
show 2 more doses
99.62 months*40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence · converted to months from 431.7 weeks as posted
62.84 months*10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence · converted to months from 272.3 weeks as posted
Dropout rate
13.2%0.5 mgg
NCT00289978 · Phase 3 · monotherapy
show 44 more results
22.6%1.25 mg
NCT00289978 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
7.7%0.5 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
13.4%1.25 mg
NCT00340834 · Phase 3 · monotherapy
13.2%0.5 mg
NCT00662649 · Phase 3 · monotherapy
—0.5 mg
NCT00662649 · Phase 3
—0.5 mg
NCT00662649 · Phase 3
22.6%1.25 mg
NCT00662649 · Phase 3 · monotherapy
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
9.1%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
13.8%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
33.3%
NCT02232061 · Phase 4 · registry result, not featured evidence
43%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
15.7%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
31%
NCT01705236 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02373098 · Phase 4 · registry result, not featured evidence
18.2%FTY720
NCT02373098 · Phase 4 · registry result, not featured evidence
0.5%
NCT01585298 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02720107 · Phase 4 · registry result, not featured evidence
8%Naive or de Novo Participants
NCT01498887 · Phase 4 · registry result, not featured evidence
7.5%Previously Treated With First-line
NCT01498887 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01333501 · Phase 4 · registry result, not featured evidence
14.2%
NCT01623596 · Phase 4 · registry result, not featured evidence
12.1%
NCT02048072 · Phase 4 · registry result, not featured evidence
16.7%
NCT01578330 · Phase 4 · registry result, not featured evidence
5.2%0.5 mg
NCT01534182 · Phase 4 · registry result, not featured evidence
9.6%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
—0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
15.6%0.5 mg/Day
NCT01201356 · Phase 3 · registry result, not featured evidence
6.8%0.5 mg
NCT01497262 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
24%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
32.2%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
2.1%
NCT01199861 · Phase 3 · registry result, not featured evidence
19.1%0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
21.7%1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
13.6%20 mgg
NCT02425644 · Phase 3
show 4 more results
19.8%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
33.9%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
35%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
38.3%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.1%0.5 mgg
NCT00289978 · Phase 3 · monotherapy
show 44 more results
5.1%1.25 mg
NCT00289978 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
2.1%0.5 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
6.1%1.25 mg
NCT00340834 · Phase 3 · monotherapy
3.1%0.5 mg
NCT00662649 · Phase 3 · monotherapy
—0.5 mg
NCT00662649 · Phase 3
—0.5 mg
NCT00662649 · Phase 3
5.1%1.25 mg
NCT00662649 · Phase 3 · monotherapy
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
0%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
2.3%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
—
NCT02232061 · Phase 4 · registry result, not featured evidence
15.2%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
5.5%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
5.7%
NCT01705236 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02373098 · Phase 4 · registry result, not featured evidence
4.5%FTY720
NCT02373098 · Phase 4 · registry result, not featured evidence
0.3%
NCT01585298 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02720107 · Phase 4 · registry result, not featured evidence
2%Naive or de Novo Participants
NCT01498887 · Phase 4 · registry result, not featured evidence
0.7%Previously Treated With First-line
NCT01498887 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01333501 · Phase 4 · registry result, not featured evidence
4.6%
NCT01623596 · Phase 4 · registry result, not featured evidence
9.1%
NCT02048072 · Phase 4 · registry result, not featured evidence
4.8%
NCT01578330 · Phase 4 · registry result, not featured evidence
3%0.5 mg
NCT01534182 · Phase 4 · registry result, not featured evidence
5.1%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
—0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
4.1%0.5 mg/Day
NCT01201356 · Phase 3 · registry result, not featured evidence
1.2%0.5 mg
NCT01497262 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
6.1%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
7.6%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
1.1%
NCT01199861 · Phase 3 · registry result, not featured evidence
12.8%0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
4.3%1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
2.3%20 mgg
NCT02425644 · Phase 3
show 4 more results
1.6%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
0.8%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
3.4%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
1.7%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Serious AEs
10.1%0.5 mgg
NCT00289978 · Phase 3 · monotherapy
show 44 more results
11.9%1.25 mg
NCT00289978 · Phase 3 · monotherapy
7%0.5 mg
NCT00340834 · Phase 3 · monotherapy
14.5%0.5 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
10.7%1.25 mg
NCT00340834 · Phase 3 · monotherapy
15.3%1.25 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00662649 · Phase 3 · monotherapy
9.4%0.5 mg
NCT00662649 · Phase 3
7.1%0.5 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
10.7%1.25 mg
NCT00662649 · Phase 3
11.7%1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
—0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
33.3%
NCT02232061 · Phase 4 · registry result, not featured evidence
5.5%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
5.5%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
12.6%
NCT01705236 · Phase 4 · registry result, not featured evidence
4.5%0.5 mg
NCT02373098 · Phase 4 · registry result, not featured evidence
—FTY720
NCT02373098 · Phase 4 · registry result, not featured evidence
2.3%
NCT01585298 · Phase 4 · registry result, not featured evidence
0%0.5 mg
NCT02720107 · Phase 4 · registry result, not featured evidence
5.5%Naive or de Novo Participants
NCT01498887 · Phase 4 · registry result, not featured evidence
2.7%Previously Treated With First-line
NCT01498887 · Phase 4 · registry result, not featured evidence
8.7%0.5 mg
NCT01333501 · Phase 4 · registry result, not featured evidence
6.7%
NCT01623596 · Phase 4 · registry result, not featured evidence
6.1%
NCT02048072 · Phase 4 · registry result, not featured evidence
9.5%
NCT01578330 · Phase 4 · registry result, not featured evidence
0.9%0.5 mg
NCT01534182 · Phase 4 · registry result, not featured evidence
4%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
3.6%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
12.6%0.5 mg/Day
NCT01201356 · Phase 3 · registry result, not featured evidence
7.4%0.5 mg
NCT01497262 · Phase 3 · registry result, not featured evidence
14.8%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
6.5%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
14.3%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
8.8%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
1.1%
NCT01199861 · Phase 3 · registry result, not featured evidence
17%0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
10.9%1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
8.7%20 mgg
NCT02425644 · Phase 3
show 4 more results
12.8%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
24.1%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
16.6%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
23%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
0.5 mgg
nasopharyngitis 27.1% (placebo 27.5%)
headache 25.2% (placebo 23%)
upper respiratory tract infection 17.2% (placebo 17.2%)
NCT00289978 · Phase 3 · monotherapy
show 34 more results
1.25 mg
headache 26.3% (placebo 23%)
nasopharyngitis 26.1% (placebo 27.5%)
upper respiratory tract infection 14.5% (placebo 17.2%)
NCT00289978 · Phase 3 · monotherapy
0.5 mg
headache 23.1%
nasopharyngitis 20.5%
fatigue 10.3%
NCT00340834 · Phase 3 · monotherapy
0.5 mg
nasopharyngitis 31%
headache 20.5%
lymphopenia 14.7%
NCT00340834 · Phase 3 · monotherapy
1.25 mg
headache 22.9%
nasopharyngitis 22.1%
fatigue 14.3%
NCT00340834 · Phase 3 · monotherapy
1.25 mg
nasopharyngitis 31.3%
lymphopenia 21.4%
headache 17.1%
NCT00340834 · Phase 3 · monotherapy
0.5 mg
nasopharyngitis 25.4%
upper respiratory tract infection 17.5%
lymphopenia 15.7%
NCT00662649 · Phase 3
0.5 mg
nasopharyngitis 28.4%
headache 16.8%
upper respiratory tract infection 15.5%
NCT00662649 · Phase 3
1.25 mg
nasopharyngitis 28.4%
lymphopenia 18%
upper respiratory tract infection 13.5%
NCT00662649 · Phase 3
1.25 mg
nasopharyngitis 26.9%
upper respiratory tract infection 15.9%
headache 12.4%
NCT00662649 · Phase 3
anxiety 16.7%
bursitis 16.7%
facet joint syndrome 16.7%
NCT02232061 · Phase 4 · registry result, not featured evidence
0.5 mg
headache 8%
lymphopenia 5.5%
pain in extremity 5.5%
NCT03257358 · Phase 4 · registry result, not featured evidence
0.5 mg
fall 5.5%
urinary tract infection 3.2%
arthralgia 2.8%
NCT03257358 · Phase 4 · registry result, not featured evidence
nasopharyngitis 47.1%
multiple sclerosis relapse 24.1%
hypertension 13.8%
NCT01705236 · Phase 4 · registry result, not featured evidence
0.5 mg
influenza 3%
gamma-glutamyltransferase increased 1.5%
headache 1.5%
NCT02373098 · Phase 4 · registry result, not featured evidence
headache 4.5%
fatigue 3.2%
nasopharyngitis 2%
NCT01585298 · Phase 4 · registry result, not featured evidence
0.5 mg
blood immunoglobulin m decreased 0.8%
NCT02720107 · Phase 4 · registry result, not featured evidence
headache 8.5%
nasopharyngitis 8%
upper respiratory tract infection 7.5%
NCT01498887 · Phase 4 · registry result, not featured evidence
headache 11.6%
urinary tract infection 10.2%
upper respiratory tract infection 8.2%
NCT01498887 · Phase 4 · registry result, not featured evidence
0.5 mg
headache 10.6%
alanine aminotransferase increased 8.7%
depression 6.7%
NCT01333501 · Phase 4 · registry result, not featured evidence
fatigue 11.3%
nasopharyngitis 9.5%
headache 9.2%
NCT01623596 · Phase 4 · registry result, not featured evidence
exacerbation of migraines 3%
NCT02048072 · Phase 4 · registry result, not featured evidence
urinary infection 21.4%
upper respiratory infection 19%
lymphopenia 16.7%
NCT01578330 · Phase 4 · registry result, not featured evidence
0.5 mg
lymphopenia 11.7%
gamma-glutamyltransferase increased 5.7%
alanine aminotransferase increased 4.8%
NCT01534182 · Phase 4 · registry result, not featured evidence
0.5 mg/day
headache 12.4%
fatigue 11.5%
upper respiratory tract infection 6.5%
NCT01216072 · Phase 4 · registry result, not featured evidence
0.5 mg/day
headache 9.8%
nausea 5.7%
fatigue 5.2%
NCT01216072 · Phase 4 · registry result, not featured evidence
0.5 mg/Day
nasopharyngitis 17.3%
headache 8.5%
upper respiratory tract infection 8.5%
NCT01201356 · Phase 3 · registry result, not featured evidence
0.5 mg
headache 13.6%
lymphopenia 10.5%
fatigue 6.2%
NCT01497262 · Phase 3 · registry result, not featured evidence
0.5 mg
upper respiratory tract infection 24.3% (placebo 24.2%)
nasopharyngitis 23.5% (placebo 23.9%)
headache 23.2% (placebo 21.4%)
NCT00355134 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 16% (placebo 23.9%)
upper respiratory tract infection 12.3% (placebo 24.2%)
headache 9% (placebo 21.4%)
NCT00355134 · Phase 3 · registry result, not featured evidence
1.25 mg
upper respiratory tract infection 24.9% (placebo 24.2%)
nasopharyngitis 23.8% (placebo 23.9%)
headache 21.9% (placebo 21.4%)
NCT00355134 · Phase 3 · registry result, not featured evidence
1.25 mg
nasopharyngitis 16.2% (placebo 23.9%)
upper respiratory tract infection 15.9% (placebo 24.2%)
sinusitis 10.1% (placebo 12.7%)
NCT00355134 · Phase 3 · registry result, not featured evidence
headache 18.9% (placebo 9.3%)
nasopharyngitis 15.8% (placebo 18.6%)
upper respiratory tract infection 11.6% (placebo 14%)
NCT01199861 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 61.7%
headache 17%
liver function test abnormal 12.8%
NCT00670449 · Phase 2 · registry result, not featured evidence
1.25 mg
nasopharyngitis 60.9%
liver function test abnormal 17.4%
lymphopenia 17.4%
NCT00670449 · Phase 2 · registry result, not featured evidence
20 mgg
alanine aminotransferase increased 19.5%
nasopharyngitis 19.3%
headache 11.3%
NCT02425644 · Phase 3
show 4 more results
20 mg
covid-19 26.2%
nasopharyngitis 18.7%
alanine aminotransferase increased 16.6%
NCT03232073 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 31.7%
headache 21.4%
upper respiratory tract infection 19.3%
NCT01093326 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 29.8%
headache 27.2%
upper respiratory tract infection 25.8%
NCT01093326 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 33.1%
headache 27.3%
upper respiratory tract infection 19.4%
NCT01093326 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fTrial phases differ: Phase 2 versus Phase 4.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fingolimod (Gilenya)

EDSS 3mo Disability Progression-free 82.3% (n=425) vs 75.9% (n=418) placebo @ 104wk0.5 mg
responder rate · % of participants
NCT00289978 · Phase 3 · monotherapy
show 3 more results
74.7% (n=358) vs 71% (n=355) placebo @ 104wk0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
83.4% (n=429) vs 75.9% (n=418) placebo @ 104wk1.25 mg
NCT00289978 · Phase 3 · monotherapy
78.3% (n=370) vs 71% (n=355) placebo @ 104wk1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
New or Enlarging T2 Lesion 2.5 vs 9.8 placebo lesions @ 104wk0.5 mg
event count · lesions
NCT00289978 · Phase 3 · monotherapy
show 1 more result
2.5 vs 9.8 placebo lesions @ 104wk1.25 mg
NCT00289978 · Phase 3 · monotherapy
Annualized Relapse 0.161 per year @ 52wk0.5 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 17 more results
0.182 per year @ 104wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
0.11 per year @ 156wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
NA per year @ 208wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
0.539 per year @ 26wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.227 per year @ 52wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.166 per year @ 104wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.191 per year @ 156wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.164 per year @ 208wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.203 per year @ 52wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.156 per year @ 104wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.116 per year @ 156wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
NA per year @ 208wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.404 per year @ 26wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.284 per year @ 52wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.223 per year @ 104wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.058 per year @ 156wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.075 per year @ 208wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
New T2 Lesion 1.6 T2 lesions @ 52wk0.5 mg
event count · T2 lesions
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 7 more results
0.87 T2 lesions @ 104wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
1.04 T2 lesions @ 156wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
0.59 T2 lesions @ 208wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
1.6 T2 lesions @ 52wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
1.08 T2 lesions @ 104wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
1.4 T2 lesions @ 156wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.97 T2 lesions @ 208wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
EDSS 3mo Disability Progression-free 94.1% (n=429) @ 52wk0.5 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 1 more result
93.3% (n=420) @ 52wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
Annualized Relapse 0.166 per year @ 234wk0.5 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
Month 0 to end of study, n=420, 429, 431
NCT00340834 · Phase 3 · monotherapy
show 1 more result
0.192 per year @ 234wk1.25 mg
Month 0 to end of study, n=420, 429, 431
NCT00340834 · Phase 3 · monotherapy
New T2 Lesion 0.86 T2 lesions @ 234wk0.5 mg
event count · T2 lesions
Extension (open-label)
No placebo or comparator arm
Last MRI scan to end of study, n=275, 309, 290
NCT00340834 · Phase 3 · monotherapy
show 1 more result
1.75 T2 lesions @ 234wk1.25 mg
Last MRI scan to end of study, n=275, 309, 290
NCT00340834 · Phase 3 · monotherapy
EDSS 6mo Disability Progression Free 71.28% (n=429) @ 13wk0.5 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 3 more results
79.76% (n=429) @ 26wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
67.01% (n=420) @ 13wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
79.54% (n=420) @ 26wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
Relapse Rate Annualized 0.185 per year @ 260wk0.5 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 9 more results
0.111 per year @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.292 per year @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.095 per year @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.13 per year @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.164 per year @ 260wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.064 per year @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.301 per year @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.074 per year @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.164 per year @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
Relapse-free 59.29% (n=425) @ 260wk0.5 mg
absolute value · percentage points
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 1 more result
59.85% (n=429) @ 260wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
no New or Enlarged T2 Lesion 50.3% (n=163) @ 104wk0.5 mg
absolute value · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 23 more results
23.2% (n=69) @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
69.3% (n=163) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
55.1% (n=69) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
69.4% (n=57) @ 13wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
86% (n=57) @ 26wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
88.6% (n=57) @ 39wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
93.2% (n=57) @ 52wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
88.4% (n=57) @ 78wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
94.9% (n=57) @ 104wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
92% (n=57) @ 156wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
100% (n=57) @ 208wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
53.2% (n=126) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
18.5% (n=65) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
57.1% (n=126) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
52.3% (n=65) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
60% (n=54) @ 13wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
91.5% (n=54) @ 26wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
92.3% (n=54) @ 39wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
95.2% (n=54) @ 52wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
90% (n=54) @ 78wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
92.3% (n=54) @ 104wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
90.5% (n=54) @ 156wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
100% (n=54) @ 208wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
Brain Volume -0.983% (n=330) @ 104wk0.5 mg
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 9 more results
-1.419% (n=154) @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
-0.78% (n=330) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
-0.903% (n=154) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
-1.674% (n=299) @ 260wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
-1.011% (n=287) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
-1.511% (n=145) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
-0.871% (n=287) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
-1.103% (n=145) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
-1.639% (n=250) @ 260wk1.25 mg
NCT00662649 · Phase 3 · monotherapy

+ 141 further endpoints in the CSV export.

Ponesimod

FSIQ-RMS Symptoms Domain -0.01 vs 3.56 Teriflunomide score @ 108wk20 mg
absolute change · score
NCT02425644 · Phase 3
CUAL Rate Annualized 1.405 vs 3.164 Teriflunomide per year @ 108wk20 mg
event rate · per year
NCT02425644 · Phase 3
Confirmed Disability Progression 12w 7.6% (n=567) vs 8.3% (n=566) Teriflunomide @ 60wk20 mg
responder rate · % of participants
NCT02425644 · Phase 3
show 1 more result
10.8% (n=567) vs 13.2% (n=566) Teriflunomide @ 108wk20 mg
NCT02425644 · Phase 3
Confirmed Disability Progression 24w 6.3% (n=567) vs 6.9% (n=566) Teriflunomide @ 60wk20 mg
responder rate · % of participants
NCT02425644 · Phase 3
show 1 more result
8.7% (n=567) vs 10.5% (n=566) Teriflunomide @ 108wk20 mg
NCT02425644 · Phase 3
Annualized Relapse 0.143 vs 0.184 Teriflunomide then Ponesimod per year20 mg
event rate · per year
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Time to First Relapse 92.93 vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence · converted to months from 402.71 weeks as posted
Time to 3m Confirmed Disability Worsening NA vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Time to CDP 6mo NA vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Relapse Free 56.7% (n=439) vs 51.6% (n=438) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
EDSS 0.16 vs 0.34 Teriflunomide then Ponesimod score20 mg
absolute change · score
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
NEDA 17.5% (n=439) vs 7.5% (n=436) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
NEDA-4 5.2% (n=437) vs 2.3% (n=435) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fingolimod (Gilenya)'s landscape · Ponesimod's landscape